Tech Company Financing Transactions
XTuit Pharmaceuticals Funding Round
On 6/11/2015, XTuit Pharmaceuticals secured $22 million in Series A investment from New Enterprise Associates, Arcus Ventures and CTI Life Sciences Fund.
Transaction Overview
Company Name
Announced On
6/11/2015
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Series A
Investors
New Enterprise Associates (Lead Investor) (David Mott)
Proceeds Purpose
Proceeds from the financing will be used to advance the development of XTuit's lead products into the clinic in oncology and liver cirrhosis and NASH and to build its biomarker platform which will enable rapid clinical proof-of-concept.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
35 Gatehouse Dr. A1
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alan Crane
Chief Scientific Officer
Peter Blume-Jensen
Browse more venture capital transactions:
Prev: 6/11/2015: TripleLift venture capital transaction
Next: 6/12/2015: Bright Funds venture capital transaction
Share this article
About Our VC Transactions Data
We report on funding rounds that are announced publicly. All VC database entries on this site are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs